- Home
- CNTX vs LIVE Comparison
CNTX vs LIVE Comparison
Compare CNTX & LIVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- LIVE
- Stock Information
- Founded
- CNTX 2015
- LIVE 1968
- Country
- CNTX United States
- LIVE United States
- Employees
- CNTX 9
- LIVE N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- LIVE Other Specialty Stores
- Sector
- CNTX Health Care
- LIVE Consumer Discretionary
- Exchange
- CNTX Nasdaq
- LIVE Nasdaq
- Market Cap
- CNTX 76.5M
- LIVE N/A
- IPO Year
- CNTX 2021
- LIVE N/A
- Fundamental
- Price
- CNTX $1.02
- LIVE $10.30
- Analyst Decision
- CNTX Strong Buy
- LIVE
- Analyst Count
- CNTX 4
- LIVE 0
- Target Price
- CNTX $7.38
- LIVE N/A
- AVG Volume (30 Days)
- CNTX 234.3K
- LIVE 4.1K
- Earning Date
- CNTX 11-06-2024
- LIVE 12-12-2024
- Dividend Yield
- CNTX N/A
- LIVE N/A
- EPS Growth
- CNTX N/A
- LIVE N/A
- EPS
- CNTX N/A
- LIVE N/A
- Revenue
- CNTX N/A
- LIVE $472,840,000.00
- Revenue This Year
- CNTX N/A
- LIVE $20.91
- Revenue Next Year
- CNTX N/A
- LIVE N/A
- P/E Ratio
- CNTX N/A
- LIVE N/A
- Revenue Growth
- CNTX N/A
- LIVE 42.48
- 52 Week Low
- CNTX $0.89
- LIVE $8.69
- 52 Week High
- CNTX $2.75
- LIVE $28.45
- Technical
- Relative Strength Index (RSI)
- CNTX 17.93
- LIVE 52.81
- Support Level
- CNTX $1.17
- LIVE $9.62
- Resistance Level
- CNTX $1.61
- LIVE $10.20
- Average True Range (ATR)
- CNTX 0.11
- LIVE 0.53
- MACD
- CNTX -0.03
- LIVE 0.13
- Stochastic Oscillator
- CNTX 9.15
- LIVE 80.10
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.